Effective antitumoral immune responses are not induced by cytosine deaminase suicide gene transfer in a syngeneic rat pancreatic carcinoma model

European Surgical Research

Volumn 38, Issue 6, 2006, Pages 513-521

  Eisold, Sven ^a   Antolovic, Dalibor ^b   Schmidt, Jan ^b   Wiessner, Reiko ^a   Klar, Ernst ^a   Von Knebel Doeberitz, Magnus ^b   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

5 Fluorocytosine; Antitumor immune response; Cytosine deaminase; Pancreatic cancer; Suicide system; Syngeneic rat tumor model

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; PRODRUG;

ADENOVIRUS VECTOR; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER REGRESSION; CANCER RESISTANCE; CELL ACTIVATION; CLONAL ANERGY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE TRANSFER; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RAT; SUICIDE GENE THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CYTOSINE DEAMINASE; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FLUCYTOSINE; GENE THERAPY; GENE TRANSFER, HORIZONTAL; MALE; PANCREATIC NEOPLASMS; RATS; RATS, INBRED LEW;

EID: 33751519303     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096070     Document Type: Article

References (33)

1. Niculescu-Duvaz I, Springer CJ: Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005;30:71-88.
2. Xu G, McLeod HL: Strategies for enzyme/ prodrug cancer therapy. Clin Cancer Res 2001;7:3314-3324.
3. Mullen CA, Coale MM, Lowe R, Blaese RM: Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res 1994;54:1503-1506.
4. Barba D, Hardin J, Sadelain M, Gage FH: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994;91:4348-4352.
5. Kaliberov SA, Chiz S, Kaliberova LN, Krendelchtchikova V, Della Manna D, Zhou T, Buchsbaum DJ: Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity. Cancer Gene Ther 2006;13:203-214.
6. Dachs GU, Tupper J, Tozer GM: From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-359.
7. Freeman SM, Ramesh R, Marrogi AJ: Immune system in suicide-gene therapy. Lancet 1997;349:2-3.
8. Mullen CA, Petropoulos D, Lowe RM: Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin-6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 1996;56:1361-1366.
9. Cao X, Ju DW, Tao Q Wang J, Wan T, Wang BM, Zhang W, Hamada H: Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Ther 1998;5:1130-1136.
10. Hwang KS, Cho WK, Yoo J, Yun HJ, Kim S, Im DS. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer 2005;5:51.
11. Pettengill OS, Faris RA, Bell RH Jr, Kuhlmann ET, Longnecker DS: Derivation of duct-like cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am J Pathol 1993;143:292-303.
12. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95:2509-2514.
13. Gerard R, Meidell RS: Adenovirus vectors; in Glover DM, Hames BD (eds): DNA Cloning 4. A Practical Approach. London, Oxford University Press, 1996, pp 285-306.
14. Haack K, Moebius U, von Knebel Doeberitz M, Herfarth C, Schackert HK, Gebert JF: Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Hum Gene Ther 1997;8:1395-1401.
15. Yoon KJ, Potter PM, Danks MK: Development of prodrugs for enzyme-mediated, tumor-selective therapy. Curr Med Chem Anticancer Agents 2005;5:107-113.
16. Consalvo M, Mullen CA, Modesti A, Musiani P, Allione A, Cavallo F, Giovarelli M, Forni G: 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995;154:5302-5312.
17. Nanni P, De Giovanni C, Nicoletti G, Landuzzi L, Rossi I, Frabetti F, Giovarelli M, Forni G, Cavallo F, Di Carlo E, Musiani P, Lol lini PL: The immune response elicited by mammary adenocarcinoma cells transduced with interferon-γ and cytosine deaminase genes cures lung metastases by parental cells. Hum Gene Ther 1998;9:217-224.
18. Smythe WR: Prodrug/drug sensitivity gene therapy: current status. Curr Oncol Rep 2000;2:17-22.
19. Pan X, Li ZS, Xu GM, Cui L, Tu ZXl: Adenovirus-mediated gene transfer in the treatment of pancreatic cancer. Pancreas 2003;26:274-278.
20. Haack K, Linnebacher M, Eisold S, Zoller M, von Knebel Doeberitz, Gebert J: Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther 2000;7:1357-1364.
21. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993;53:4619-4626.
22. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004;363:1049-1057.
23. Lockhart AC, Rothenberg ML, Berlin JD: Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-1654.
24. Fearon ER, Itaya T, Hunt B, Vogelstein B, Frost P: Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res 1988;48:2975-2980.
25. Nabel GJ, Chang AE, Nabel EG, Plautz GE, Ensminger W, Fox BA, Felgner P, Shu S, Cho K: Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994;5:57-77.
26. Ackerman AL, Cresswell P: Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 2004;5:678-684.
27. Colombo MP, Modesti A, Parmiani G; Forni G: Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res 1992;52:4853-4857.
28. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G: Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992;149:3627-3635.
29. Pardoll D: New strategies for active immunotherapy with genetically engineered tumor cells. Curr Opin Immunol 1992;4:619-623.
30. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-965.
31. Forni G, Cavallo F, Consalvo M, Allione A, Dellabona P, Casorati G, Giovarelli M: Molecular approaches to cancer immunotherapy. Cytokines Mol Ther 1995;1:225-248.
32. Cavallo F, Di Pierro F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, et al: Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993;53:5067-5070.
33. Gilliam AD, Watson SA: Emerging biological therapies for pancreatic carcinoma. Eur J Surg Oncol 2002;28:370-378.